| Identification | More | [Name]
Tacalcitol | [CAS]
57333-96-7 | [Synonyms]
Tacalcitol
1-alpha-3-beta-5E,7E,24R)-9,10-Secocholesta-5,7,10,19-triene-1,3,24-triol
trans-Calcitriol
1a,24(R)-Dihydroxycholecalciferol
1a,24(R)-Dihydroxyvitamin D3
1a,24R-Dihydroxyvitamin D3
9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, (1a,3b,5Z,7E,24R)-(9CI)
Bonalfa
Curatoderm
PRI 2191
TV 02
1ALPHA,24(R)-DIHYDROXYVITAMIND3
(1α，3β-5Z，7E，24R)-9，10-Secoholesta-5，7，10(19)-triene-1，3，24-triol
lα，24-Dihydroxycholecalciferol
lα，24R-Dihy-droxyvitamin D3
[5Z,7E,24R,(+)]-9,10-Secocholesta-5,7,10(19)-triene-1α,3β,24-triol
1α,24(R)-Dihydroxyvitamin D3
1α,24R-Dihydroxyvitamin D3
(1a,3b,5Z,7E,24R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol | [Molecular Formula]
C27H44O3 | [Molecular Weight]
416.636 | [MOL File]
57333-96-7.mol |
| Chemical Properties | Back Directory | [Boiling point ]
565.0±50.0 °C(Predicted) | [density ]
1.06 | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
20mg/mL in DMSO, 20mg/mL in DMF, 20mg/mL in Ethanol | [form ]
Powder | [pka]
14.43±0.40(Predicted) | [color ]
White to off-white | [biological source]
synthetic (organic) | [InChIKey]
BJYLYJCXYAMOFT-RSFVBTMBSA-N | [SMILES]
[C@@H]1(O)C/C(=C/C=C2\CCC[C@@]3(C)[C@@]\2([H])CC[C@@H]3[C@H](C)CC[C@@H](O)C(C)C)/C(=C)[C@@H](O)C1 | [CAS DataBase Reference]
57333-96-7(CAS DataBase Reference) |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS06 | [Signal word ]
Danger | [Hazard statements ]
H300 | [Precautionary statements ]
P264-P270-P301+P310-P321-P330-P405-P501 | [WGK Germany ]
WGK 3 | [Storage Class]
6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials | [Hazard Classifications]
Acute Tox. 1 Oral | [Safety Profile]
A poison by ingestion, subcutaneous, and intravenous routes. When heated to decomposition it emits acrid smoke and irritating vapors, |
| Hazard Information | Back Directory | [Description]
Tacalcitol, the second vitamin D analog developed as a topical antipsoriatic, was
introduced for keratosis, psoriasis, ichthyosis, pityriasis rubra pilaris and palmoplantar
pustulosis and keratoderma. It shows improvement in appearance of skin lesions for psoriasis
patients without significant side effects. In patients with psoriasis vulgaris, it effectively
inhibits keratinocyte growth. Some in vitro studies have shown that tacalcitol inhibits
interleukin-1-α-induced granulocyte macrophage colony-stimulating-factor mRNA expression
of the human dermal microvascular endothelial cells, which may be involved in mediation of
angioproliferation in skin inflammation. | [Originator]
Teijin
(Japan) | [Uses]
Tacalcitol is a synthetic vitamin D3 analog. | [Definition]
ChEBI: Tacalcitol is a hydroxy seco-steroid that is calciol which carries hydroxy groups at positions 1S and 24R. It is a vitamin D3 analog which is used for the treatment of psoriasis vulgaris in adults, especially on the scalp. It has a role as an antipsoriatic, a vitamin D receptor agonist and an antineoplastic agent. It is a member of D3 vitamins, a hydroxy seco-steroid, a secondary alcohol and a seco-cholestane. It is functionally related to a calciol. | [Brand name]
Bonalfa |
|
|